

< .

>

: . (2003-17 ,
2003.4.14.) 3 2 7 가 (. , .)

	가	
	()	()
	10, 20, 40mg	10, 20, 40mg
	1 () 10.85, 21.69, 43.38 mg (10, 20, 40mg)	1 () 10.85, 21.69, 43.38 mg (10, 20, 40mg)
	10mg, 20mg	10mg, 20mg
1)	: 1) : _____, _____ (55 _____), _____, _____ HDL- _____ 가 _____)가 가. _____	: 1) : _____, _____ (55 _____), _____, _____ HDL- _____ 가 _____)가 가. _____
2)	(Type a b) () 2) _____ 가 _____ (Fredrickson Type a b) , LDL- _____, _____ _____, _____ -B, _____ _____ HDL- _____ 가 _____	(Type III) () (Type III) 4) _____ 가 _____ _____, LDL- _____ _____, _____ (, LDL-apheresis) _____ 가 _____
3)	(Type III)	(Type III)
4)	가 _____ 가 _____ 10 - 17 (_____), , _____ -B, _____, LDL- _____ 가. LDL- _____ 190 mg/dL (190 mg/dL) . LDL- _____ 160 mg/dL (160 mg/dL),	5) 가 _____ 가 _____ 가 10 - 17 (_____), LDL- _____, _____ -B 가. LDL- _____ 190 mg/dL (190 mg/dL) . LDL- _____ 160 mg/dL (160 mg/dL),

	가	
	()	()
	10, 20, 40mg	10, 20, 40mg
	가 가 가	가 가 가
	40mg	40mg
1)	_____ : _____ : _____, _____, HDL- (55 _____), _____가 _____)가 가. _____ .	1) _____ : _____ : _____, _____, HDL- (55 _____), _____가 _____)가 가. _____ .
2)	_____ (_____) _____ (Type a b) _____, LDL- _____, _____ -B _____,	2) _____ (_____ 가 가) _____ (_____) _____ (Fredrickson Type a b) _____, LDL- _____, _____ -B, _____ _____ HDL- _____ 가
3)	(Type III)	3) _____ (Type III)
		4) _____ 가 _____ _____, LDL- _____ _____ (_____, LDL-apheresis) _____, _____ 가 가 _____
	10mg, 20mg	10mg, 20mg
	_____ . _____ _____ 1 1 10mg . LDL- _____ _____, _____ _____ 4 _____ _____ 1 _____ 80mg _____	_____ . _____
1)	_____ (_____) _____ _____ 1 1 10mg _____ 2 _____ 4 _____	1) _____ (_____ 가 가) _____ (_____) _____ (Fredrickson Type a b) : _____ 1 1 10 mg _____ _____ 20 mg _____ . LDL- _____ _____ 가 _____ (45% _____), 1 _____ 1 40 mg _____ 1 1 10 mg ~ 80 mg

	가	
	()	()
	10, 20, 40mg	10, 20, 40mg
		<p>_____ , _____ .</p> <p>_____ / _____ .</p> <p>_____ , 2 ~ 4 _____ .</p> <p>_____ , _____ .</p> <p>LDL _____ , NCEP _____ 가 LDL- _____ . LDL- _____ 가 가 _____ .</p>
2) 가 (2) 가 (10 ~ 17) (10 ~ 17) : 1 10mg , 1 10 mg , 1 20mg . (20mg) 1 20 mg . (20 mg) . 4 . 4 .		<p>3) 가 : 가 1 10 ~ 80 mg . 가 (, LDL apheresis) _____ , _____ 가 _____ .</p> <p>4) _____ 가 (bile acid binding resin) _____ HMG-CoA _____ (_____) _____ .</p>
3) LDL- 가 .		5) LDL- 가 .
4) 70		6) : 70

	가	
	()	()
	10, 20, 40mg	10, 20, 40mg
	40mg	40mg
	1 1 10mg . LDL-	
	4	
	1	
	80mg	
1)	()	1) (가 가)
	1 1 10mg	(Fredrickson Type a b):
	2	1 1 10 mg
	4	20 mg . LDL-
		가 (45%), 1
		1 40 mg . 1
		1 10 mg ~ 80 mg
		/
		2 ~ 4
		LDL
		, NCEP
		가 LDL-
		. LDL- 가 가
2)	1 80mg	2) 1 80mg
		3) 가 :
		가
		1 10 ~ 80 mg .
		가
		(, LDL apheresis)
		가
		4) 가 (bile

	가	
	()	()
	10, 20, 40mg	10, 20, 40mg
		acid binding resin)
		HMG-CoA
		(
		-
3)	LDL-	5) LDL-
	가 .	가 .
4)		6) :
70		70

1.

2.

- 1) Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease
- 2) Effects of Atorvastatin on Early Recurrent Ischemic Events in Acute Coronary Syndromes The MIRACL Study : a randomized controlled trial
- 3) A Multi-center, Eight-week, Double-blind assessment comparing the efficacy and safety of Atorvastatin at starting dose of 10mg, 20mg, 40mg and 80mg
- 4) An 8-week, open-label, pilot study to assess the efficacy and safety of atorvastatin in patients with homozygous familial hypercholesterolemia

3.

- 1) : Pfizer "Lipitor 10mg, 20mg, 40mg, 80mg"
- 2) : Pfizer Ireland Pharmaceuticals "Lipitor 10mg, 20mg, 40mg, 80mg"